Summary:
In patients with diabetic kidney disease (DKD), vonoprazan 20 mg daily significantly reduced proteinuria (albumin/creatinine ratio) and stabilized renal function (eGFR) compared to lansoprazole 30 mg daily, though it was associated with no significant adverse effects reported over three months.
| PICO | Description |
|---|---|
| Population | Adults with diabetic kidney disease (including 100 patients treated for H. pylori eradication and 40 patients for other indications). |
| Intervention | Vonoprazan 20 mg daily administered for three months. |
| Comparison | Lansoprazole 30 mg daily administered for three months. |
| Outcome | Vonoprazan significantly reduced albumin/creatinine ratio, indicating attenuated proteinuria, and preserved estimated glomerular filtration rate (eGFR) compared with lansoprazole. No significant adverse events were observed during the study period. |
Source: Rabab Mahmoud Ahmed. “Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism.” Read article here.
